IG
ALDR

ING Group’s Alder Biopharmaceuticals ALDR Stock Holding History

ING Group’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-350,000
Closed -$4.01M – 867
2017
Q4 		$4.01M Hold
350,000
– – 0.07% 145
2017
Q3 		$4.29M Buy
350,000
+15,000
+4% +$156K 0.08% 162
2017
Q2 		$3.84M Buy
+335,000
New +$6.19M 0.07% 151

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ING Group's ALDR Position: Q1 2018 in Review

ING Group sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 350,000 shares — an estimated $4.01M sold.

ING Group first reported a position in ALDR in Q2 2017 and held it in 3 quarters. The position peaked at $4.29M in Q3 2017. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • ING Group reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • ING Group sold 350,000 Alder Biopharmaceuticals shares in Q1 2018, an estimated $4.01M.
  • ING Group first reported a position in Alder Biopharmaceuticals in Q2 2017 and held it in 3 quarters.
  • ING Group's Alder Biopharmaceuticals position peaked at $4.29M in Q3 2017.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on ING Group's 13F filing for Q1 2018, filed 7 May 2018.